Template:Medications and dosages used in hormone therapy for transgender women
Medication | Brand name | Type | Route | Dosage[b] |
---|---|---|---|---|
Estradiol | Various | Estrogen | Oral | 2–10 mg/day |
Various | Estrogen | Sublingual | 1–8 mg/day | |
Climara[c] | Estrogen | TD patch | 25–400 μg/day | |
Divigel[c] | Estrogen | TD gel | 0.5–5 mg/day | |
Various | Estrogen | SC implant | 50–200 mg every 6–24 mos | |
Estradiol valerate | Progynova | Estrogen | Oral | 2–10 mg/day |
Progynova | Estrogen | Sublingual | 1–8 mg/day | |
Delestrogen[c] | Estrogen | IM, SC | 2–10 mg/wk or 5–20 mg every 2 wks | |
Estradiol cypionate | Depo-Estradiol | Estrogen | IM, SC | 2–10 mg/wk or 5–20 mg every 2 wks |
Estradiol dipropionate | Agofollin | Estrogen | IM, SC | 2–10 mg/wk or 5–20 mg every 2 wks |
Estradiol benzoate | Progynon-B | Estrogen | IM, SC | 0.5–1.5 mg every 2–3 days |
Estriol | Ovestin[c] | Estrogen | Oral | 4–6 mg/day |
Spironolactone | Aldactone | Antiandrogen | Oral | 100–400 mg/day |
Cyproterone acetate | Androcur | Antiandrogen; Progestogen |
Oral | 5–100 mg/day |
Androcur Depot | IM | 300 mg/month | ||
Bicalutamide | Casodex | Antiandrogen | Oral | 25–50 mg/day |
Enzalutamide | Xtandi | Antiandrogen | Oral | 160 mg/day |
GnRH analogue
|
Various | GnRH modulator | Various | Variable |
Elagolix | Orilissa | GnRH antagonist | Oral | 150 mg/day or 200 mg twice daily |
Finasteride | Propecia | 5αR inhibitor | Oral | 1–5 mg/day |
Dutasteride | Avodart | 5αR inhibitor | Oral | 0.25–0.5 mg/day |
Progesterone | Prometrium[c] | Progestogen | Oral | 100–400 mg/day |
Medroxyprogesterone acetate | Provera | Progestogen | Oral | 2.5–40 mg/day |
Depo-Provera | Progestogen | IM | 150 mg every 3 mos | |
Depo-SubQ Provera 104 | Progestogen | SC | 104 mg every 3 mos | |
Hydroxyprogesterone caproate | Proluton | Progestogen | IM | 250 mg/wk |
Dydrogesterone | Duphaston | Progestogen | Oral | 20 mg/day |
Drospirenone | Slynd | Progestogen | Oral | 3 mg/day |
Domperidone[d] | Motilium | Prolactin releaser | Oral | 30–80 mg/day[e] |
|
Template documentation
See also
- Template:Estrogen dosages for menopausal hormone therapy
- Template:Estrogen dosages for breast and prostate cancer
- Template:Medications and dosages used in hormone therapy for transgender men
References
- S2CID 3726467.
- ^ Deutsch M (17 June 2016). "Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People" (PDF) (2nd ed.). University of California, San Francisco: Center of Excellence for Transgender Health. p. 28.
- ^ Dahl M, Feldman JL, Goldberg J, Jaberi A, Bockting WO, Knudson G (2015). "Endocrine Therapy for Transgender Adults in British Columbia: Suggested Guidelines" (PDF). Vancouver Coastal Health. Retrieved 15 August 2018.
- ^ Bourns A (2015). "Guidelines and Protocols for Comprehensive Primary Care for Trans Clients" (PDF). Sherbourne Health Centre. Retrieved 15 August 2018.
- S2CID 144632597. Archived from the original(PDF) on 2018-09-02.
- PMID 28159148.
- PMID 28078219.
- S2CID 52821192.
- S2CID 73253356.
- S2CID 86772102.
- S2CID 12270365.
- S2CID 8001811.
- PMID 21449788.
- ISBN 978-1-315-34513-0.
- ISBN 978-88-470-5696-1.
- S2CID 207503049.
- ISBN 978-3-319-19752-4.
- PMID 27916515.
- S2CID 222189278.
- PMID 17986639.
- S2CID 199033008.
- S2CID 39706760.
- PMID 24830596.
- PMID 12915619.
- PMID 25140398.
- ^ Arver DS (2015). "Transsexualism, könsdysfori". Retrieved 2018-11-12.
- PMID 26830952.
- S2CID 144580633.
- S2CID 24493388.
- ISBN 978-3-662-45018-5.
- PMID 30671393.
When we prescribed estradiol, we preferred sublingual estradiol valerate instead of the oral form for feminizing HT since prior researchers have reported the effectiveness of sublingual administration in maintaining high blood estradiol concentration and low E1/E2 ratio [13].
- ISBN 978-1-56639-852-7.
- S2CID 218596936.
- PMID 29372185.
- PMID 12674062.
- ^ "Orilissa (elagolix) FDA Label" (PDF). 24 July 2018. Retrieved 31 July 2018.